Pan-cancer analysis of DNA epigenetic modifications by hydrophilic interaction liquid chromatography-tandem mass spectrometry

• Published in: Chinese chemical letters 2023-07, Vol.34 (7), p.108023-218, Article 108023
• Main Authors: Hu, Yiqiu, Hong, Xiujuan, Yuan, Zhijun, Mu, Jiayi, Zhang, Xiaoxiao, Fang, Zhihao, Yuan, Ying, Zheng, Shu, Guo, Cheng
• Format: Article
• Language: English
• Subjects: 5-Hydroxymethyl-2′-deoxycytidine; 5-Methyl-2′-deoxycytidine; HILIC-MS/MS; N6-methyl-2′-deoxyadenosine; Pan-cancer analysis
• ISSN: 1001-8417; 1878-5964
• DOI: 10.1016/j.cclet.2022.108023

Accumulating evidence in recent years indicates that DNA methylation (5-methyl-2′-deoxycytidine, 5-mdC) and hydroxymethylation (5-hydroxymethyl-2′-deoxycytidine, 5-hmdC) have been implicated in various biological processes, and the aberrations of these DNA cytosine modifications is tightly associated with cancer. N6-methyl-2′-deoxyadenosine (m6dA), as a newly discovered epigenetic modification in genome of mammals, has been demonstrated to play vital regulatory roles in tumorigenesis. However, the content information of m6dA in human tumor tissues is still limited and pan-cancer analysis of these DNA epigenetic modifications is lacked. Herein, we developed a sensitive and robust stable isotope-diluted hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) method for accurate quantification of m6dA, 5-mdC and 5-hmdC in genomic DNA from 82 pairs of human tumor tissues and matched tumor-adjacent normal tissues. The types of tumors included esophagus cancer, lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, stromal tumor and colorectal cancer. Compared to the normal tissues, we revealed the level of m6dA was increased in tumor tissues of esophagus cancer, lung cancer and liver cancer, whereas the level of m6dA was diminished in tumor tissues of pancreatic cancer and gastric cancer; while the contents of 5-mdC and 5-hmdC exhibited significant decrease in tumor tissues of most types of cancer. It is worth noting that we revealed, for the first time, the content of genomic m6dA in pancreatic cancer, stromal tumor and colorectal cancer. The significant changes of these DNA epigenetic modifications indicate they may serve as indicators of cancers. In addition, this study will benefit for better understanding of the regulatory roles of these DNA epigenetic modifications in cancers. We performed accurate quantification and evaluation of the alterations of DNA epigenetic modifications in various types of cancer by HILIC-MS/MS, and the content of genomic m6dA was revealed, for the first time, in pancreatic cancer, stromal tumor and colorectal cancer. The results suggested that these DNA epigenetic modifications could be potential indicators for cancer diagnosis and prognosis. [Display omitted]